Inhibition of Polo-like kinase 1 (PLK1) synergizes with Vemurafenib in the treatment of melanoma.

(A and B) Immunoblots of cleaved-PARP (c-PARP) and p-ERK detected in A375 (A) and A375R (B) cells after 48 h treatment of either DMSO, Vemurafenib, Volasertib, or a combination of Vemurafenib and Volasertib, respectively. (C–E) Percentages of apoptotic...

সম্পূর্ণ বিবরণ

সংরক্ষণ করুন:

গ্রন্থ-পঞ্জীর বিবরন
প্রধান লেখক:	Fengyi Mao (15073242) (author)
অন্যান্য লেখক:	Sai Wu (6096290) (author), Derek B. Allison (15141675) (author), Daheng He (9189701) (author), Yifan Kong (4458616) (author), Chaohao Li (15141681) (author), Zhiguo Li (431917) (author), Yanquan Zhang (14930570) (author), Xinyi Wang (559030) (author), Qiongsi Zhang (2818111) (author), Chi Wang (131921) (author), Xiaoqi Liu (45630) (author)
প্রকাশিত:	2025
বিষয়গুলি:	Cell Biology Genetics Molecular Biology Developmental Biology Cancer Hematology Biological Sciences not elsewhere classified suppress tumor growth like kinase 1 crucial transcription factor cnc homolog 1 clinical database analysis shortened mice survival >< sup >< div >< p cutaneous melanoma based v600e </ sup patient survival pten </ ca </ ></ sup synergistic efficiency novel function negatively correlates genes involved cell cycle cancer progression cancer metabolism bach1 ), >- deficiency
ট্যাগগুলো:	ট্যাগ যুক্ত করুন কোনো ট্যাগ নেই, প্রথমজন হিসাবে ট্যাগ করুন!

Inhibition of Polo-like kinase 1 (PLK1) synergizes with Vemurafenib in the treatment of melanoma.

অনুরূপ উপাদানগুলি